While a small sampling, BIO's third diversity report provides 'benchmark' for data-focused industry to further analyze
The numbers are somewhat in and biotech diversity looks relatively similar to what it has been for years.
A 2021 sampling paints a very limited picture of the industry, with BIO’s third annual diversity report including only 99 respondent companies. Most questions were not or could not be answered by every single organization, meaning many went unanswered, such as insight on board-level demographics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.